Javier Torres Corredor

Uptake of bone modifying agents in patients with HER2 metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry.

Vanessa Wong, Richard de Boer, Catherine Dunn, Angelyn Anton, Laeeq Malik, Sally Greenberg, Belinda Yeo, Louise Nott, Ian M Collins, Javier Torres, Frances Barnett, Michelle Nottage, Peter Gibbs, Sheau Wen Lok

Journal article  |  2021  |  Intern Med J

BACKGROUND AND AIM: International practice guidelines recommend administration of bone modifying agents (BMA) in metastatic breast..

Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status

Avraham Travers, Azim Jalali, Stephen Begbie, Christine Semira, Suzanne Kosmider, Sumitra Ananda, Rachel Wong, Margaret Lee, Jeremy Shapiro, Matthew Burge, Desmond Yip, Javier Torres, Brigette Ma, Louise Nott, Andrew Dean, Jeanne Tie, Adnan Khattak, Stephanie Lim, Hui-li Wong, Peter Gibbs

Journal article  |  2021  |  CLINICAL COLORECTAL CANCER

BACKGROUND: The management of metastatic colorectal cancer patients with a poor performance status (PS) continues to be a clinical..

OA05.06 Lessons Learned from the Victorian Lung Cancer Registry: Opportunities for Quality Improvement in Lung Cancer Management and Outcomes

R Stirling, M Brand, A Earnest, P Antippa, D Ball, J Bartlett, R Blum, L Briggs, M Caldecott, M Conron, B Jennings, D Langton, J Millar, P Mitchell, I Olesen, P Parente, G Richardson, K See, J Torres, C Underhill, et al.

Journal article  |  2021  |  Journal of Thoracic Oncology

Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center

Mike Nguyen, Tate Jacobson, Javier Torres, Alysson Wann

Journal article  |  2021  |  CANCER REPORTS

BACKGROUND: Febrile neutropenia is a serious complication of chemotherapy. The Multinational Association for Supportive Care in Ca..

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience.

Rachel Raju, Arvind Sahu, Myron Klevansky, Javier Torres

Journal article  |  2021  |  Front Oncol

Background: Both abiraterone and enzalutamide have shown to improve overall survival (OS), progression-free survival (PFS) and pro..

Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience

R Raju, A Sahu, M Klevansky, J Torres

Conference Proceedings  |  2020  |  ANNALS OF ONCOLOGY

Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease

Andrew Schmidt, Angelyn Anton, Julia Shapiro, Shirley Wong, Arun Azad, Edmond Kwan, Lavinia Spain, Arun Muthusamy, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Anthony M Joshua, David Pook, Peter Gibbs, Ben Tran, Andrew Weickhardt

Journal article  |  2020  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

AIM: Optimal treatment for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved, with many patients de..

Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancer

C Conduit, RH de Boer, S Lok, P Gibbs, L Malik, Z Loh, B Yeo, S Greenberg, B Devitt, J Lombard, M Nottage, I Collins, J Torres, M Nolan, L Nott

Journal article  |  2020  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

BACKGROUND: Anti-HER2 therapy-related cardiotoxicity is well described in the context of clinical trials, particularly in the sett..

Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer

Yada Kanjanapan, Sheau Wen Lok, Peter Gibbs, Richard De Boer, Belinda Yeo, Sally Greenberg, Frances Barnett, Louise Knott, Gary Richardson, Rachel Wong, Michelle Nottage, Ian M Collins, Javier Torres, Janine Lombard, Julie Johns, Michael Harold, Laeeq Malik

Journal article  |  2020  |  BREAST CANCER RESEARCH AND TREATMENT

PURPOSE: Trastuzumab, pertuzumab, and docetaxel are the standard first-line therapy for HER2-positive (HER2+) metastatic breast ca..

Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 /HR metastatic breast cancer.

Matthew Loft, Sheau Wen Lok, Richard H De Boer, Laeeq Malik, Sally Greenberg, Belinda Yeo, Angelyn Anton, Louise M Nott, Gary Edward Richardson, Ian M Collins, Javier Torres, Frances Sarah Barnett, Bianca Alix Devitt, Peter Gibbs, Lucy Gately

Journal article  |  2020  |  Journal of Clinical Oncology

1038 Background: The combination of dual anti-HER2 targeted therapy and chemotherapy is the current first line standard of care f..